anmelden
OMX Copenhagen PI
1.348,92
PKT
+4,30
PKT
+0,32
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.08.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.08.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.08.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 04.08.22 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 04.08.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.08.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 03.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 18.07.22 | Novo Nordisk Overweight | Barclays Capital | |
| 14.07.22 | Novo Nordisk Outperform | Bernstein Research | |
| 13.07.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 12.07.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 01.07.22 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 28.06.22 | Novo Nordisk Sell | UBS AG | |
| 24.06.22 | Novo Nordisk Neutral | UBS AG | |
| 24.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.06.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 16.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 13.06.22 | Novo Nordisk Overweight | Barclays Capital | |
| 13.06.22 | DSV A-S Buy | UBS AG | |
| 08.06.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 07.06.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.06.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 03.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 27.05.22 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 24.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 20.05.22 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 12.05.22 | Novo Nordisk Overweight | Barclays Capital | |
| 11.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.05.22 | Novo Nordisk Outperform | Bernstein Research | |
| 05.05.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 29.04.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 29.04.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 29.04.22 | Novo Nordisk Outperform | Bernstein Research | |
| 29.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 28.04.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 27.04.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 21.04.22 | Novo Nordisk Outperform | Bernstein Research |
